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Background: Squamous cell carcinomas (SCC) account for approximately 30% of non-small cell lung cancer.
Investigation of the mechanism of invasion and metastasis of lung SCC will be of great help for the development
of meaningful targeted therapeutics. This study is intended to understand whether the activation of Hedgehog
(Hh) pathway is involved in lung SCC, and whether activated Hh signaling regulates metastasis through
epithelial-mesenchymal transition (EMT) in lung SCC.
Methods: Two cohorts of patients with lung SCC were studied. Protein expression was examined by
immunohistochemistry, Western blot, or immunofluorescence. Protein expression levels in tissue specimens were
scored and correlations were analyzed. Vismodegib and a Gli inhibitor were used to inhibit Shh/Gli activity, and
recombinant Shh proteins were used to stimulate the Hh pathway in lung SCC cell lines. Cell migration assay was
performed in vitro.
Results: Shh/Gli pathway components were aberrantly expressed in lung SCC tissue samples. Gli1 expression
was reversely associated with the expression of EMT markers E-Cadherin and β-Catenin in lung SCC specimens.
Inhibition of the Shh/Gli pathway suppressed migration and up-regulated E-Cadherin expression in lung SCC cells.
Stimulation of the pathway increased migration and down-regulated E-Cadherin expression in lung SCC cells.
Conclusions: Our results suggested that the Shh/Gli pathway may be critical for lung SCC recurrence, metastasis
and resistance to chemotherapy. Inhibition of the Shh/Gli pathway activity/function is a potential therapeutic
strategy for the treatment of lung SCC patients.
Keywords: Sonic Hedgehog, Gli, EMT, Lung squamous cell carcinomaBackground
Lung cancer is the leading cause of cancer-related deaths
worldwide. 85% of lung cancer is non-small cell lung can-
cer (NSCLC), with adenocarcinoma (AD) and squamous
cell carcinoma (SCC) as the two major pathological sub-
types [1]. Lung SCC is closely associated with tobacco
smoking, and it accounts 35% of NSCLC, causing an esti-
mated 400,000 deaths per year worldwide [2]. While recent* Correspondence: yuedongsheng_cg@163.com; biao.he@ucsfmedctr.org
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unless otherwise stated.improvements in targeted therapies such as the EGFR
tyrosine kinase inhibitors (TKI), bevacizumab and ALK in-
hibitors have significantly benefited patients with AD, the
effectiveness of these treatments are unfortunately disap-
pointing for lung SCC [3]. Lung SCC patients suffer from
poor prognosis with significant rates of reoccurrence and
metastasis, largely due to the differences in genetic profiles
[4]. Recent studies identified potentially actionable genetic
abnormalities in lung SCC, such as phosphoinositide 3-
kinase (PIK3CA) amplification, fibroblast growth factor
receptor 1 (FGFR1) amplification, and discoidin domain
receptor 2 (DDR2) mutation. However, significant efforts
are still needed to help in the investigation of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cipher and the mechanism underlying the invasion and
metastasis of lung SCC.
Epithelial–mesenchymal transition (EMT) was ori-
ginally characterized during embryonic development.
The concept that EMT being a critical event in the in-
vasion, progression and metastasis of epithelial cancers
is well established [5,6]. The molecular basis of EMT in-
volves multiple changes in expression, distribution, and/or
function of proteins, i.e. E-cadherin, and the process of
EMT is regulated by many molecular events including
multiple signaling pathways in various cancers [5]. Fur-
thermore, acquisition of the features of the EMT has been
associated with poor prognosis and chemo-resistance,
which may allow for recurrence and metastasis to occur
after treatment with a standard chemotherapeutic treat-
ment [7-10]. The mechanistic study of EMT regulation
could contribute to our understanding of recurrence and
metastasis in cancer.
Activation of Hedgehog (Hh) signaling has been impli-
cated in tumorigenesis and metastasis in various cancer
types [11-23]. Hh signaling is orchestrated by two trans-
membrane receptors, Patched (Ptch) and Smoothened
(Smo). In the canonical Hh pathway, in the absence of
the Hh ligand, Ptch inhibits Smo, causing cleavage of Gli
to the N-terminal repressor form. Once Hh binds to
Ptch, the inhibitory effect on Smo is released, causingFigure 1 Aberrant activation of the Shh pathway in lung SCC. (A) Rep
staining, scored as 0 (negative), 1 (mild positive), 2 (positive), and 3 (strong
177 patient tissue specimens in the Tianjin cohort. (C) Association between
was used to determine the correlation between proteins. The correlation c
performed with IHC scores of 1–3 grouped as “+”, 0 as “-”. Kappa test’s p vaactive full-length Gli to transport into the nucleus and
activate transcription of Hh target genes in a context-
and cell-type specific manner. Moreover, several studies
have revealed "non-canonical Gli activation" in many
cancer cell types by which Gli is activated independent
of Hh/Smo regulation [12,14]. It needs to be elucidated
if the canonical Hh pathway or the non-canonical Gli ac-
tivation is involved in lung SCC, and if Gli activation
contributes to the regulation of metastasis.
Studies of EMT regulation by Hh pathway have re-
cently emerged in literature; data, however, is rare and
controversial. While Alexaki et al. [24] and Inaguma
et al. [25] suggested that Gli-factor facilitates cancer cell
migration and invasion through E-Cadherin in melan-
oma and pancreatic cancers, Joost et al. [26] proposed
that inhibition of Gli promoted EMT in pancreatic can-
cers. Our study intends to extend the research to lung
SCC to help us better understand the regulation of EMT
by Hh signaling.
We reported the activation of Hh signaling in two co-
horts of patient samples, and revealed the reverse associ-
ation between Gli1 expression and the expression of
EMT markers. Inhibition of the Shh/Gli pathway sup-
pressed migration and up-regulated E-Cadherin expres-
sion in lung SCC cells. Stimulation of the pathway
increased migration and down-regulated E-Cadherin ex-
pression in lung SCC cells.resentative protein expression of Shh, Smo, Ptch1 and Gli1 by IHC
positive). (B) Expression distributions of Shh, Smo, Ptch1 and Gli1 in
the expressions of Hh pathway components. Kendall’s tau-b statsitcs
oefficient r and p values were presented in (C). Kappa test was also
lues were labeled with*.
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Tissue specimens
Tissue specimens of the UCSF cohort were collected
from 14 patients who underwent surgical resection for
lung SCC at the Thoracic Oncology Program at UCSF.
Tissue specimens of the Tianjin cohort were collected
from 177 patients who underwent surgical resection for
lung SCC at the Tianjin Medical University Cancer Insti-
tute and Hospital. Samples were fixed in formalin and
embedded in paraffin to make tissue slides. The study
with UCSF patient tissues was approved by the Commit-
tee on Human Research (CHR approval number:
H8714-11647-10) at the University of California, San
Francisco (UCSF), and that with Tianjin cohort was ap-
proved by the Tianjin Medical University Cancer Insti-
tute and Hospital. Written, informed consent was













Lobectomy 143 80.8%Immunohistochemistry (IHC), immunofluorescence (IF)
and Western blot
Immunohistochemistry, immunofluorescence and western
blot were performed following standard procedures. Anti-
bodies applied to detect protein expressions in IHC and IF
were Gli1 (sc-20687 Santa Cruz Biotechnology, Santa Cruz,
CA) at 1:100, Shh (ab 50515 Abcam, Cambridge, MA) at
1:100, Smo (ab 72130 Abcam) at 1:200, Ptch1 (Santa Cruz
that Biotechnology,) and E-Cadherin (EMD Millipore)
Smo (Sigma, St. Louis, MO) at 1:100, E-cadherin (sc-7870,
Santa Cruz Biotechnology) at 1:100, and β-catenin (BD
Biosciences, San Jose, California) at 1:400. Antibodies
used in Western blot were Gli (C68H3, Abcam) at
1:1000, E-Cad (HECD-1 MED Milliopore, Darmstadt,
Germany) at 1:1000 and Actin (A5441, Sigma) at 1:5000.
Total protein extraction was performed with M-PER Mam-
malian Protein Extraction Solution (Thermo Scientific,
Waltham, MA), and 40ug of proteins were analyzed in













IIIA 38 21.5%Cell culture, drug treatment and migration assay
Human lung SCC cell lines H2170, H1703, H1869 and
SK-MES-1 were purchased from the Cell Culture Core
Facility at Harvard University (Boston, MA, USA). The
cell lines were cultured in RPMI 1640 (Life Technologies,
Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS) and antibiotics. Cells were seeded one day
before treatment with Gli-I and vismodegib (Selleck) at
different concentrations and Shh recombinant proteins
(eBioscience) for 30 hours, with vehicle (DMSO) as
controls. Cells were subjected to the following analyses
of immunofluorescence and migration assay. In migra-
tion assays, four wounds were made in each condition,
and cell migration was presented by the average of dis-
tance differences between 30 hr and 0 hr. All experimentshave been conducted for more than three times, and rep-
resentative results were included in the text.
Statistical analysis
Kappa test was used to evaluate the association between
the expressions of Hh pathway components and EMT
markers, and between Gli1 and recurrence/metastasis.
IHC scores of 1–3 were grouped as positive “+” , and 0
was grouped as negative “-” for dichotomized analysis.
Non-parametric Kendall’s tau-b statistics was used to de-
termine the correlation between IHC staining of Hh
components. Two-sided student’s t-test was performed
for migration assays. A p value <0.05 was indicated as *,
0.01 as **, and 0.001 as *** in corresponding figures.
Data analysis was performed using SPSS 17.0 software.
Results and discussion
Aberrant activation of the Shh pathway in lung SCC
We first investigated the protein expression of key
Shh pathway components in lung SCC tissue samples.
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mens were collected from 177 lung SCC patients
who underwent surgical resection at the Lung Cancer
Center at Tianjin Medical University Cancer Institute
and Hospital. The protein expressions of Shh, Smo,
Ptch1 and Gli1 were characterized by immunohisto-
chemistry (IHC), and scored on a scale of 0–3 (negative,
mild positive, positive, and strong positive). Representative
samples in each score category were summarized in
Figure 1A. More than 90% of the lung SCC tissue sam-
ples examined were positive for the signal molecule
Shh, while 53% and 61% were positive for down-
stream components and transcriptional targets Ptch1
and Gli1 respectively (Figure 1B). Previous studies
have demonstrated limited expressions of Shh componentsFigure 2 Gli1 expression reversely correlates with E-Cadherin express
three representative tissue specimens in the UCSF cohort with Gli1 express
panels). (B) Expressions of Gli1, E-Cad and β-Catenin (β-Cat) in three repres
a low level (upper panels), a mixed expression pattern (middle panels) and
and recurrence/metastasis. Statistical analysis was performed between Gli1
and E-Cad expression in four lung SCC cell lines by Western blots.in normal lung tissues at the mRNA and protein levels
in NSCLC [27,28], therefore the expression of key
Shh signaling components indicates the activation of
Shh pathway. No significant association was found
between expressions of Shh, Smo, Ptch1 and Gli1 and
patients’ characteristics (sex, age, tumor size, or de-
gree of tumor differentiation) (Table 1) (P > 0.05, data
note shown).
Next we analyzed the association between expressions
of key components in the Shh pathway. Kendall’s tau-b
correlation tests yielded significant correlations between
every two factors (p = 0.000), while Kappa’s test sug-
gested strong positive association between SHh and Gli1
(p = 0.000) (Figure 1C), suggesting the canonical Shh
pathway is activated in lung SCC. These data are consistention in lung SCC. (A) Expressions of Gli1 and E-Cadherin (E-Cad) in
ion at a low level (upper panels) and high levels (middle and lower
entative tissue specimens in the Tianjin cohort with Gli1 expression at
a high level (lower panels). (C) Correlations between Gli1, EMT markers,
and E-Cad, Gli1 and β-Cat, Gli1 and recurrence/ metastasis. (D) Gli1
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has correlations with downstream targets in NSCLC
[29,30]. Taken together, our results suggest that aber-
rant activation of the Shh pathway plays an important
role in lung SCC.
Gli expression reversely correlates with EMT markers
E-Cadherin is a well-established EMT biomarker, and
its expression has been suggested to be associated with
cancer recurrence and metastasis [5]. The expression of
β-Catenin also serves as a biomarker for EMT [31]. To
investigate whether the Shh/Gli signaling plays a role in
EMT regulation in lung SCC, we first examined 14 lung
SCC patients who underwent surgical resection for
lung SCC at the Thoracic Oncology Program at UCSF.
Eight of fourteen samples showed reverse correlation
between E-Cadherin and Gli1 expressions (three repre-
sentative samples were shown in Figure 2A). To con-
firm the reverse correlation between EMT markers andFigure 3 Shh/Gli signaling promotes cell migration in lung SCC. (A) W
treated with Gli-I, vismodegib, and recombinant Shh proteins. Representative
(×100). (B) Quantification of the wound healing assays. The migration distanc
as *, ** or *** respectively.Gli1 expressions in lung SCC, we further analyzed E-
Cadherin and β-Catenin expressions and correlated
with Gli1 expression in the Tianjin cohort. Our results
revealed strong reverse correlations between Gli1 and
E-Cadherin (p = 0.003), as well as Gli1 and β-Catenin
(p = 0.004) (Figures 2B and C). We also observed re-
verse correlation between Gli1 and E-Cadherin expres-
sion at different areas within one sample in multiple
cases due to the heterogeneity of tumor cells (Figure 2),
further supporting the reverse correlation between Gli1
and EMT marker expressions. Moreover, our analysis
revealed that Gli1 significantly correlated with recur-
rence and metastasis of lung SCC in the Tianjin cohort
(p = 0.033; Figure 2C). Consistent with the tissue ex-
pression analysis, we observed that Gli1 expression re-
versely correlated with E-Cadherin expression in four
human lung SCC cell lines, H1703, H1869, H2170 and
SK-MES-1 (Figure 2D). Taken together, our results in-
dicate the essential role of Gli1, a downstream effectoround healing assays of lung SCC H2170 cells (left) and H1703 (right)
pictures shown at 0 hr and 30 hr were taken under a light microscope
e of cells was set as 100%. A p value <0.05 < 0.01 or <0.001 was indicated
Figure 4 Shh/Gli signaling down-regulates E-Cadherin expression. Immunofluorescent staining of E-Cad (green) in lung SCC H2170 cells
treated with Gli-I, vismodegib, and recombinant Shh proteins. DAPI (blue) was used to stain nuclei of those cells.
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motes recurrence and metastasis in lung SCC.
Shh/Gli signaling promotes cell migration by
down-regulating E-Cadherin expression
To further understand the role of Shh/Gli in EMT regula-
tion in lung SCC, we manipulated the Shh/Gli signaling
pathway in lung SCC cell lines to examine its impact on
cell migration and E-Cadherin expression. To inhibit the
Shh/Gli activity, we applied two small molecule com-
pounds: Vismodegib and a novel Gli inhibitor. Vismode-
gib (also known as GDC-0449) is a Smo inhibitor recently
approved by the U.S. Food and Drug Administration to
treat adult patients with basal cell carcinoma [32-35].
Multiple clinical trials are evaluating the use of vismode-
gib in other types of cancer, in addition to other candidate
drugs that targets Hh signaling [32,36]. The novel Gli in-
hibitor (Gli-I) developed by our lab specifically inhibits
Gli1 and Gli2 transcriptional activity [28]. To stimulate
the pathway, we applied recombinant Shh proteins.
We first performed cell migration assay in lung SCC
cell lines H1703 and H2170 after the treatments with
either Shh/Gli inhibitors or recombinant Shh proteins.
Cells treated with Vismodegib and Gli-I exhibited sig-
nificantly slower migration in 30 hours; on the other
hand, cells stimulated by Shh proteins migrated signifi-
cantly faster (Figure 3). This data strongly suggests that
Shh/Gli signaling plays an essential role in regulating
the migration of lung SCC cells. Next we examined
E-Cadherin expression in these cells by immunofluores-
cence staining. We observed that E-Cadherin expression
was up-regulated in those lung SCC cells treated with
Shh/Gli inhibitors and down-regulated in the cells stimu-
lated by Shh proteins (Figure 4). This is consistent
with the mobility of lung SCC cells after the different
treatments (Figure 3). Therefore, our results indicate that
Shh/Gli signaling may promote cell migration by down-
regulating E-Cadherin expression in lung SCC.Conclusions
Our study provides evidence for aberrant activation of
Shh/Gli pathway and a strong association between expres-
sions of Gli proteins and EMT markers in human lung
SCC, as well as the implication of activated Shh/Gli path-
way in cell migration and EMT process. Our findings
suggest that the Shh/Gli pathway may be a critical compo-
nent in lung SCC recurrence, metastasis and resistance to
chemotherapy. Inhibition of the Shh/Gli pathway activity/
function is a potential therapeutic strategy for the treat-
ment of lung SCC patients.
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